<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In bone marrow transplantation (BMT) the main reason for early treatment failure is transplant-associated mortality (TAM) due to GvHD, interstitial <z:hpo ids='HP_0002090'>pneumonia</z:hpo>, <z:e sem="disease" ids="C0948441" disease_type="Disease or Syndrome" abbrv="VOD">veno-occlusive disease</z:e> and <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Since 1981, 84 consecutive HLA-identical BMT have been performed (13 <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, 61 <z:hpo ids='HP_0001909'>leukemia</z:hpo>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 3 genetic diseases; mean age 28 [5-51] years) according to a standardized protocol designed to reduce TAM: fractionated, low dose rate irradiation; strict laminar air flow isolation plus complete intestinal decontamination; <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> therapy for 4 months and CMV prophylaxis (hyperimmune plasma infusion, CMV-negative blood products) </plain></SENT>
<SENT sid="2" pm="."><plain>11 patients (13%) died in TAM </plain></SENT>
<SENT sid="3" pm="."><plain>Continuous complete remission was obtained in 78% of standard risk patients (n = 55) and 28% of high risk patients (n = 29) </plain></SENT>
<SENT sid="4" pm="."><plain>Mean observation time was 42 (3-116) months post transplantation </plain></SENT>
<SENT sid="5" pm="."><plain>This result points to the necessity of a liberal indication for BMT early in the course of <z:hpo ids='HP_0011009'>acute</z:hpo> or <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo>, in the course of <z:hpo ids='HP_0011009'>acute</z:hpo> or <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo>, severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and other eventually lethal hemato-oncological diseases </plain></SENT>
</text></document>